We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SO icon
326
PUT
Southern Company
SO
$107B
$2K ﹤0.01%
+5,000
New +$251K
TCOM icon
327
CALL
Trip.com Group
TCOM
$26.7B
$2K ﹤0.01%
6,200
-2,300
-27% -$100K
TEX icon
328
CALL
Terex
TEX
$7.47B
$2K ﹤0.01%
16,200
-2,300
-12% -$52.6K
MDVN
329
PUT
DELISTED
MEDIVATION, INC.
MDVN
$2K ﹤0.01%
+1,500
New +$85K
QLIK
330
CALL
DELISTED
QLIK TECHNOLOGIES INC COM STK (DE)
QLIK
$2K ﹤0.01%
+25,500
New +$760K
ABBV icon
331
PUT
AbbVie
ABBV
$450B
$1K ﹤0.01%
16,600
-32,500
-66% -$1.98M
CLDX icon
332
CALL
Celldex Therapeutics
CLDX
$2.77B
$1K ﹤0.01%
+480
New +$30.5K
IONS icon
333
PUT
Ionis Pharmaceuticals
IONS
$8.99B
$1K ﹤0.01%
+200
New +$6.45K
KMI icon
334
CALL
Kinder Morgan
KMI
$71.9B
$1K ﹤0.01%
15,600
ODP
335
CALL
DELISTED
ODP
ODP
$1K ﹤0.01%
+2,350
New +$115K
SVXY icon
336
PUT
ProShares Short VIX Short-Term Futures ETF
SVXY
$219M
$1K ﹤0.01%
+20,000
New +$1.08M
TNXP icon
337
CALL
Tonix Pharmaceuticals
TNXP
$198M
0
OTIC
338
CALL
DELISTED
Otonomy, Inc.
OTIC
$1K ﹤0.01%
+700
New +$10.4K
CASC
339
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1K ﹤0.01%
8,650
-59,383
-87% -$403K
AEGR
340
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$1K ﹤0.01%
36,000
-31,900
-47% -$73K
ABBV icon
341
AbbVie
ABBV
$450B
-9,906
Closed -$604K
ACAD icon
342
Acadia Pharmaceuticals
ACAD
$4.38B
-108
Closed -$3.61K
ACAD icon
343
PUT
Acadia Pharmaceuticals
ACAD
$4.38B
-62,900
Closed -$5K
ADBE icon
344
CALL
Adobe
ADBE
$94.3B
-10,000
Closed -$188K
APH icon
345
PUT
Amphenol
APH
$186B
-40,000
Closed -$2K
ATHM icon
346
CALL
Autohome
ATHM
$2.48B
-26,100
Closed -$32K
AVGO icon
347
CALL
Broadcom
AVGO
$1.76T
-54,280
Closed -$54K
AVGO icon
348
Broadcom
AVGO
$1.76T
-1,170
Closed -$18K
AVGO icon
349
PUT
Broadcom
AVGO
$1.76T
-54,980
Closed -$154K
BA icon
350
CALL
Boeing
BA
$169B
-45,000
Closed -$144K

Similar funds

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.